<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506350</url>
  </required_header>
  <id_info>
    <org_study_id>109817</org_study_id>
    <nct_id>NCT00506350</nct_id>
  </id_info>
  <brief_title>Evaluate Reactogenicity &amp; Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults</brief_title>
  <official_title>Evaluate the Reactogenicity &amp; Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 &amp; 61 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The present study is designed to evaluate the reactogenicity and immunogenicity of one or two
      booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults
      aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate
      vaccine. Fifty new subjects who did not participate in a primary study (106750, NCT00309634)
      will be recruited. This protocol posting deals with objectives &amp; outcome measures of the
      booster phase. The objectives &amp; outcome measures of the primary phase are presented in a
      separate protocol posting (NCT00309634)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed to evaluate the reactogenicity and immunogenicity of one or two
      booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults
      aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate
      vaccine. The persistence of antibodies will be analysed at 6, 12, 18 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2007</start_date>
  <completion_date type="Actual">October 12, 2009</completion_date>
  <primary_completion_date type="Actual">October 12, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 0</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion rate for HI antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 0</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, headache, myalgia, shivering, sweating and fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 21-day (Days 0-20) follow-up period after the first vaccination and 30-day (Days 0-29) follow-up period after the second vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 30-day (Days 0-29) follow-up period after the first vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (From Day 0 up to Month 24)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 0, 21 (post-vaccination one) and 42 (post-vaccination two)</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005. No subject from GSK1562902A AD F1 Primed Group has received a second vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 0, 7, 14, 21, 28, 35 and 42</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 7,14, 21, 35 and 42</time_frame>
    <description>Seroconversion (SCR) was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer&lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 21 (post-vaccination one) and 42 (post-vaccination two)</time_frame>
    <description>Seroconversion rate for anti-HA antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Seroconversion rate for neutralizing antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 7, 14, 21, 35 and 42</time_frame>
    <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strains assessed were A/Indonesia/05/2005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Days 0, 7, 14, 21, 28, 35 and 42</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection.
The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection. The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed wwere H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</measure>
    <time_frame>At Months 6, 12, 18 and 24</time_frame>
    <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed were H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1562902A non-AD F1 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A non-AD F2 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A non-AD F3 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A non-AD F4 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A AD F1 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A AD F2 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A AD F3 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A AD Approved F4 Primed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose</intervention_name>
    <description>A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.</description>
    <arm_group_label>GSK1562902A AD Approved F4 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A AD F3 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A AD F1 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A AD F2 Primed Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses</intervention_name>
    <description>Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.</description>
    <arm_group_label>GSK1562902A non-AD F2 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A non-AD F4 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A non-AD F1 Primed Group</arm_group_label>
    <arm_group_label>GSK1562902A non-AD F3 Primed Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol should be enrolled in the study.

          -  For previously primed subjects: participation in the primary study (NCT00309634).

          -  For unprimed subjects: male or female between and including, 19 and 61 years of age at
             the time of the first vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2 months
             after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  For unprimed subjects who did not participate in the primary study (NCT00309634):
             Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/ administration of a licenced vaccine not foreseen by the study
             protocol within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) of
             the first dose of vaccine(s).

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Applicable for control group only: previous vaccination with a pandemic candidate
             vaccine or a vaccine containing the investigational vaccine adjuvant.

          -  History of hypersensitivity to vaccines.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Major congenital defects or serious chronic illness.

          -  History of any neurological disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  Serious chronic disease including any medically significant chronic pulmonary,
             cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined
             by medical history and physical examination.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participation in the study.

          -  Lactating female.

          -  History of chronic alcohol consumption and/or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>September 11, 2017</results_first_submitted>
  <results_first_submitted_qc>September 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2017</results_first_posted>
  <disposition_first_submitted>February 4, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 4, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 9, 2011</disposition_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109817</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK1562902A Non-AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK1562902A Non-AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK1562902A Non-AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>GSK1562902A Non-AD F4 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Control Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P6">
          <title>GSK1562902A AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P7">
          <title>GSK1562902A AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P8">
          <title>GSK1562902A AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P9">
          <title>GSK1562902A AD Approved F Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="35"/>
                <participants group_id="P8" count="41"/>
                <participants group_id="P9" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="33"/>
                <participants group_id="P8" count="36"/>
                <participants group_id="P9" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1562902A Non-AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK1562902A Non-AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK1562902A Non-AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>GSK1562902A Non-AD F4 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Control Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>GSK1562902A AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B7">
          <title>GSK1562902A AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B8">
          <title>GSK1562902A AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B9">
          <title>GSK1562902A AD Approved F Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="36"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="35"/>
            <count group_id="B8" value="41"/>
            <count group_id="B9" value="35"/>
            <count group_id="B10" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="12.80"/>
                    <measurement group_id="B2" value="36.3" spread="12.36"/>
                    <measurement group_id="B3" value="36.8" spread="12.87"/>
                    <measurement group_id="B4" value="39.5" spread="13.27"/>
                    <measurement group_id="B5" value="32.1" spread="9.96"/>
                    <measurement group_id="B6" value="38.5" spread="13.43"/>
                    <measurement group_id="B7" value="38.3" spread="14.61"/>
                    <measurement group_id="B8" value="34.8" spread="14.57"/>
                    <measurement group_id="B9" value="35.9" spread="12.78"/>
                    <measurement group_id="B10" value="36.32" spread="12.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White - Arabic / North African heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Caucasian / European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.9" upper_limit="5.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.8" upper_limit="6.5"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.9" upper_limit="5.8"/>
                    <measurement group_id="O4" value="5.2" lower_limit="4.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.8" lower_limit="225.9" upper_limit="732.7"/>
                    <measurement group_id="O2" value="429.5" lower_limit="281.2" upper_limit="655.9"/>
                    <measurement group_id="O3" value="208.4" lower_limit="126.3" upper_limit="343.9"/>
                    <measurement group_id="O4" value="347.9" lower_limit="213.6" upper_limit="566.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion rate for HI antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion rate for HI antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="44.5" upper_limit="143.6"/>
                    <measurement group_id="O2" value="76.5" lower_limit="50.7" upper_limit="115.6"/>
                    <measurement group_id="O3" value="39.1" lower_limit="24.2" upper_limit="63.1"/>
                    <measurement group_id="O4" value="76.9" lower_limit="51.5" upper_limit="115.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, headache, myalgia, shivering, sweating and fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, headache, myalgia, shivering, sweating and fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Arthralgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Arthralgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 21-day (Days 0-20) follow-up period after the first vaccination and 30-day (Days 0-29) follow-up period after the second vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 30-day (Days 0-29) follow-up period after the first vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (From Day 0 up to Month 24)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005. No subject from GSK1562902A AD F1 Primed Group has received a second vaccination.</description>
        <time_frame>At Days 0, 21 (post-vaccination one) and 42 (post-vaccination two)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005. No subject from GSK1562902A AD F1 Primed Group has received a second vaccination.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" lower_limit="34.2" upper_limit="64.6"/>
                    <measurement group_id="O2" value="157.8" lower_limit="130.3" upper_limit="191.2"/>
                    <measurement group_id="O3" value="19.9" lower_limit="15.7" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="692.4" lower_limit="476.7" upper_limit="1005.7"/>
                    <measurement group_id="O3" value="307.3" lower_limit="262.5" upper_limit="359.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="933.1" lower_limit="653.7" upper_limit="1331.9"/>
                    <measurement group_id="O2" value="3708.9" lower_limit="2458.6" upper_limit="5594.9"/>
                    <measurement group_id="O3" value="1606.4" lower_limit="1282.7" upper_limit="2011.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which included all subjects who had serologic results available at the antibody persistence time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which included all subjects who had serologic results available at the antibody persistence time-point.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1422.2" lower_limit="916.8" upper_limit="2206.2"/>
                    <measurement group_id="O2" value="502.3" lower_limit="349.2" upper_limit="722.5"/>
                    <measurement group_id="O3" value="751.3" lower_limit="611.4" upper_limit="923.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557.6" lower_limit="354.0" upper_limit="878.4"/>
                    <measurement group_id="O2" value="180.7" lower_limit="121.3" upper_limit="269.2"/>
                    <measurement group_id="O3" value="274.4" lower_limit="215.7" upper_limit="349.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="767.5" lower_limit="494.8" upper_limit="1190.6"/>
                    <measurement group_id="O2" value="278.5" lower_limit="173.7" upper_limit="446.5"/>
                    <measurement group_id="O3" value="569.9" lower_limit="442.9" upper_limit="733.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503.2" lower_limit="338.3" upper_limit="748.4"/>
                    <measurement group_id="O2" value="201.6" lower_limit="143.2" upper_limit="283.8"/>
                    <measurement group_id="O3" value="295.4" lower_limit="237.8" upper_limit="367.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Days 0, 7, 14, 21, 28, 35 and 42</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, whiich included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, whiich included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.9" upper_limit="5.3"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="11.7" upper_limit="41.8"/>
                    <measurement group_id="O2" value="25.3" lower_limit="14.5" upper_limit="44.4"/>
                    <measurement group_id="O3" value="27.7" lower_limit="16.1" upper_limit="47.6"/>
                    <measurement group_id="O4" value="37.6" lower_limit="19.3" upper_limit="73.4"/>
                    <measurement group_id="O5" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" lower_limit="24.0" upper_limit="90.7"/>
                    <measurement group_id="O2" value="66.1" lower_limit="39.7" upper_limit="109.9"/>
                    <measurement group_id="O3" value="49.1" lower_limit="25.7" upper_limit="93.8"/>
                    <measurement group_id="O4" value="71.5" lower_limit="39.0" upper_limit="131.2"/>
                    <measurement group_id="O5" value="13.7" lower_limit="9.6" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="20.4" upper_limit="70.6"/>
                    <measurement group_id="O2" value="57.6" lower_limit="36.9" upper_limit="90.0"/>
                    <measurement group_id="O3" value="42.2" lower_limit="23.0" upper_limit="77.4"/>
                    <measurement group_id="O4" value="77.1" lower_limit="45.1" upper_limit="131.7"/>
                    <measurement group_id="O5" value="31.0" lower_limit="20.8" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" lower_limit="26.1" upper_limit="88.7"/>
                    <measurement group_id="O2" value="79.3" lower_limit="52.7" upper_limit="119.3"/>
                    <measurement group_id="O3" value="56.0" lower_limit="31.2" upper_limit="100.4"/>
                    <measurement group_id="O4" value="128.0" lower_limit="81.8" upper_limit="200.4"/>
                    <measurement group_id="O5" value="543.9" lower_limit="423.3" upper_limit="698.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="28.6" upper_limit="109.8"/>
                    <measurement group_id="O2" value="119.9" lower_limit="77.5" upper_limit="185.5"/>
                    <measurement group_id="O3" value="65.8" lower_limit="36.1" upper_limit="120.2"/>
                    <measurement group_id="O4" value="160.0" lower_limit="100.8" upper_limit="254.2"/>
                    <measurement group_id="O5" value="563.6" lower_limit="438.5" upper_limit="724.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="27.9" upper_limit="105.8"/>
                    <measurement group_id="O2" value="116.3" lower_limit="77.2" upper_limit="175.4"/>
                    <measurement group_id="O3" value="63.7" lower_limit="34.5" upper_limit="117.9"/>
                    <measurement group_id="O4" value="141.4" lower_limit="92.3" upper_limit="216.7"/>
                    <measurement group_id="O5" value="443.0" lower_limit="335.6" upper_limit="584.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="40"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="10.9" upper_limit="28.4"/>
                    <measurement group_id="O2" value="17.6" lower_limit="11.6" upper_limit="26.6"/>
                    <measurement group_id="O3" value="18.5" lower_limit="12.1" upper_limit="28.5"/>
                    <measurement group_id="O4" value="24.3" lower_limit="16.5" upper_limit="35.9"/>
                    <measurement group_id="O5" value="17.8" lower_limit="12.3" upper_limit="25.9"/>
                    <measurement group_id="O6" value="81.5" lower_limit="43.4" upper_limit="153.0"/>
                    <measurement group_id="O7" value="82.5" lower_limit="47.7" upper_limit="142.7"/>
                    <measurement group_id="O8" value="42.1" lower_limit="24.9" upper_limit="71.0"/>
                    <measurement group_id="O9" value="47.3" lower_limit="27.5" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="11.7" upper_limit="32.8"/>
                    <measurement group_id="O2" value="17.5" lower_limit="11.3" upper_limit="27.2"/>
                    <measurement group_id="O3" value="22.4" lower_limit="15.0" upper_limit="33.7"/>
                    <measurement group_id="O4" value="19.0" lower_limit="12.8" upper_limit="28.2"/>
                    <measurement group_id="O5" value="16.2" lower_limit="10.9" upper_limit="23.9"/>
                    <measurement group_id="O6" value="100.2" lower_limit="53.5" upper_limit="187.6"/>
                    <measurement group_id="O7" value="108.0" lower_limit="61.1" upper_limit="190.9"/>
                    <measurement group_id="O8" value="59.7" lower_limit="34.8" upper_limit="102.3"/>
                    <measurement group_id="O9" value="64.7" lower_limit="37.9" upper_limit="110.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="34"/>
                    <count group_id="O9" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="8.2" upper_limit="20.8"/>
                    <measurement group_id="O2" value="22.9" lower_limit="15.3" upper_limit="34.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="13.0" upper_limit="32.3"/>
                    <measurement group_id="O4" value="33.3" lower_limit="22.1" upper_limit="50.3"/>
                    <measurement group_id="O5" value="12.0" lower_limit="8.1" upper_limit="18.0"/>
                    <measurement group_id="O6" value="55.4" lower_limit="28.4" upper_limit="108.4"/>
                    <measurement group_id="O7" value="65.3" lower_limit="36.0" upper_limit="118.3"/>
                    <measurement group_id="O8" value="42.5" lower_limit="25.7" upper_limit="70.4"/>
                    <measurement group_id="O9" value="55.3" lower_limit="31.2" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="35"/>
                    <count group_id="O9" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.6" upper_limit="14.9"/>
                    <measurement group_id="O2" value="9.0" lower_limit="6.7" upper_limit="12.0"/>
                    <measurement group_id="O3" value="9.4" lower_limit="6.5" upper_limit="13.6"/>
                    <measurement group_id="O4" value="8.7" lower_limit="6.4" upper_limit="11.8"/>
                    <measurement group_id="O5" value="10.9" lower_limit="7.4" upper_limit="16.1"/>
                    <measurement group_id="O6" value="38.0" lower_limit="20.1" upper_limit="71.8"/>
                    <measurement group_id="O7" value="31.2" lower_limit="16.9" upper_limit="57.7"/>
                    <measurement group_id="O8" value="21.9" lower_limit="12.7" upper_limit="37.5"/>
                    <measurement group_id="O9" value="22.9" lower_limit="12.9" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion (SCR) was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
        <time_frame>At Days 7,14, 21, 35 and 42</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion (SCR) was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer&lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer&lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="40"/>
                    <count group_id="O9" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="34"/>
                    <count group_id="O9" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="35"/>
                    <count group_id="O9" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion rate for anti-HA antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>At Days 21 (post-vaccination one) and 42 (post-vaccination two)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion rate for anti-HA antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion rate for neutralizing antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion rate for neutralizing antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
        <time_frame>At Days 7, 14, 21, 35 and 42</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.3" upper_limit="8.2"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.9" upper_limit="8.9"/>
                    <measurement group_id="O3" value="5.5" lower_limit="3.2" upper_limit="9.5"/>
                    <measurement group_id="O4" value="7.5" lower_limit="3.9" upper_limit="14.7"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="4.7" upper_limit="17.7"/>
                    <measurement group_id="O2" value="13.2" lower_limit="7.9" upper_limit="22.0"/>
                    <measurement group_id="O3" value="9.8" lower_limit="5.1" upper_limit="18.8"/>
                    <measurement group_id="O4" value="14.3" lower_limit="7.8" upper_limit="26.2"/>
                    <measurement group_id="O5" value="2.7" lower_limit="1.9" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="11.5" lower_limit="7.4" upper_limit="18.0"/>
                    <measurement group_id="O3" value="8.4" lower_limit="4.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="15.4" lower_limit="9.0" upper_limit="26.3"/>
                    <measurement group_id="O5" value="6.2" lower_limit="4.2" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="5.6" upper_limit="21.4"/>
                    <measurement group_id="O2" value="24.0" lower_limit="15.5" upper_limit="37.1"/>
                    <measurement group_id="O3" value="13.2" lower_limit="7.2" upper_limit="24.0"/>
                    <measurement group_id="O4" value="32.0" lower_limit="20.2" upper_limit="50.8"/>
                    <measurement group_id="O5" value="112.7" lower_limit="87.7" upper_limit="144.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="5.5" upper_limit="20.7"/>
                    <measurement group_id="O2" value="23.3" lower_limit="15.4" upper_limit="35.1"/>
                    <measurement group_id="O3" value="12.7" lower_limit="6.9" upper_limit="23.6"/>
                    <measurement group_id="O4" value="28.3" lower_limit="18.5" upper_limit="43.3"/>
                    <measurement group_id="O5" value="88.6" lower_limit="67.1" upper_limit="116.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strains assessed were A/Indonesia/05/2005.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strains assessed were A/Indonesia/05/2005.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="40"/>
                    <count group_id="O9" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.1" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="3.7" lower_limit="2.4" upper_limit="5.7"/>
                    <measurement group_id="O4" value="4.9" lower_limit="3.3" upper_limit="7.2"/>
                    <measurement group_id="O5" value="3.6" lower_limit="2.5" upper_limit="5.2"/>
                    <measurement group_id="O6" value="15.0" lower_limit="8.0" upper_limit="28.2"/>
                    <measurement group_id="O7" value="14.1" lower_limit="8.1" upper_limit="24.2"/>
                    <measurement group_id="O8" value="7.9" lower_limit="4.8" upper_limit="13.1"/>
                    <measurement group_id="O9" value="9.8" lower_limit="5.8" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.3" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.2" upper_limit="4.9"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.0" upper_limit="6.7"/>
                    <measurement group_id="O4" value="3.8" lower_limit="2.6" upper_limit="5.6"/>
                    <measurement group_id="O5" value="3.2" lower_limit="2.2" upper_limit="4.8"/>
                    <measurement group_id="O6" value="18.3" lower_limit="9.8" upper_limit="34.2"/>
                    <measurement group_id="O7" value="18.3" lower_limit="10.4" upper_limit="32.1"/>
                    <measurement group_id="O8" value="11.2" lower_limit="6.7" upper_limit="18.9"/>
                    <measurement group_id="O9" value="13.6" lower_limit="8.1" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="34"/>
                    <count group_id="O9" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.1" upper_limit="6.9"/>
                    <measurement group_id="O3" value="4.1" lower_limit="2.6" upper_limit="6.5"/>
                    <measurement group_id="O4" value="6.7" lower_limit="4.4" upper_limit="10.1"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.6" upper_limit="3.6"/>
                    <measurement group_id="O6" value="10.1" lower_limit="5.2" upper_limit="19.7"/>
                    <measurement group_id="O7" value="11.5" lower_limit="6.5" upper_limit="20.3"/>
                    <measurement group_id="O8" value="7.9" lower_limit="4.9" upper_limit="12.8"/>
                    <measurement group_id="O9" value="11.6" lower_limit="6.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="35"/>
                    <count group_id="O9" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.3" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.3" upper_limit="2.4"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.3" upper_limit="2.7"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.3" upper_limit="2.4"/>
                    <measurement group_id="O5" value="2.2" lower_limit="1.5" upper_limit="3.2"/>
                    <measurement group_id="O6" value="6.9" lower_limit="3.7" upper_limit="13.0"/>
                    <measurement group_id="O7" value="5.9" lower_limit="3.2" upper_limit="10.7"/>
                    <measurement group_id="O8" value="4.1" lower_limit="2.4" upper_limit="6.8"/>
                    <measurement group_id="O9" value="4.7" lower_limit="2.6" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection.
The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
        <time_frame>At Days 0, 7, 14, 21, 28, 35 and 42</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection.
The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
        <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection. The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Non-AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1562902A Non-AD F4 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK1562902A AD F2 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK1562902A AD F3 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O9">
            <title>GSK1562902A AD Approved F Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain</title>
          <description>Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection. The flu strain assessed was A/Indonesia/05/2005 (H5N1).</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/05/2005, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="40"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="34"/>
                    <count group_id="O9" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/05/2005, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="35"/>
                    <count group_id="O9" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</title>
        <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed wwere H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</title>
          <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed wwere H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="743.00" lower_limit="524.00" upper_limit="991.00"/>
                    <measurement group_id="O2" value="1370.00" lower_limit="776.00" upper_limit="1599.00"/>
                    <measurement group_id="O3" value="473.50" lower_limit="277.50" upper_limit="757.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1945.50" lower_limit="1104.50" upper_limit="2737.50"/>
                    <measurement group_id="O2" value="2504.00" lower_limit="1515.00" upper_limit="4252.00"/>
                    <measurement group_id="O3" value="2721.00" lower_limit="2040.00" upper_limit="4072.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="682.50" lower_limit="475.00" upper_limit="1044.50"/>
                    <measurement group_id="O2" value="1284.50" lower_limit="839.00" upper_limit="1831.00"/>
                    <measurement group_id="O3" value="540.00" lower_limit="379.00" upper_limit="873.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1870.00" lower_limit="1179.50" upper_limit="2806.50"/>
                    <measurement group_id="O2" value="2640.50" lower_limit="1217.00" upper_limit="4211.00"/>
                    <measurement group_id="O3" value="2607.00" lower_limit="1973.00" upper_limit="3738.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709.00" lower_limit="484.50" upper_limit="1014.00"/>
                    <measurement group_id="O2" value="1363.50" lower_limit="721.00" upper_limit="1546.00"/>
                    <measurement group_id="O3" value="457.50" lower_limit="280.50" upper_limit="738.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1874.00" lower_limit="1093.50" upper_limit="2657.50"/>
                    <measurement group_id="O2" value="2480.00" lower_limit="1501.00" upper_limit="3972.00"/>
                    <measurement group_id="O3" value="2633.00" lower_limit="1894.00" upper_limit="4033.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.00" lower_limit="470.50" upper_limit="1011.00"/>
                    <measurement group_id="O2" value="1288.50" lower_limit="832.00" upper_limit="1830.00"/>
                    <measurement group_id="O3" value="525.50" lower_limit="366.00" upper_limit="832.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1842.50" lower_limit="1145.50" upper_limit="2727.00"/>
                    <measurement group_id="O2" value="2652.00" lower_limit="1218.00" upper_limit="4039.00"/>
                    <measurement group_id="O3" value="2580.50" lower_limit="1847.00" upper_limit="3578.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641.00" lower_limit="419.50" upper_limit="847.00"/>
                    <measurement group_id="O2" value="1186.50" lower_limit="773.00" upper_limit="1492.00"/>
                    <measurement group_id="O3" value="433.50" lower_limit="273.50" upper_limit="671.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1616.00" lower_limit="1044.00" upper_limit="2475.00"/>
                    <measurement group_id="O2" value="2291.50" lower_limit="1474.00" upper_limit="3648.00"/>
                    <measurement group_id="O3" value="2485.00" lower_limit="1800.00" upper_limit="3839.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.50" lower_limit="381.50" upper_limit="931.50"/>
                    <measurement group_id="O2" value="1195.50" lower_limit="744.00" upper_limit="1635.00"/>
                    <measurement group_id="O3" value="473.50" lower_limit="339.00" upper_limit="778.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1607.00" lower_limit="1064.00" upper_limit="2588.50"/>
                    <measurement group_id="O2" value="2210.00" lower_limit="1120.00" upper_limit="3828.00"/>
                    <measurement group_id="O3" value="2368.50" lower_limit="1840.00" upper_limit="3458.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.00" lower_limit="282.00" upper_limit="626.00"/>
                    <measurement group_id="O2" value="607.00" lower_limit="388.00" upper_limit="873.00"/>
                    <measurement group_id="O3" value="357.00" lower_limit="203.50" upper_limit="518.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785.50" lower_limit="472.00" upper_limit="1453.00"/>
                    <measurement group_id="O2" value="1304.50" lower_limit="613.00" upper_limit="1829.00"/>
                    <measurement group_id="O3" value="993.50" lower_limit="735.00" upper_limit="1840.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.00" lower_limit="233.50" upper_limit="731.00"/>
                    <measurement group_id="O2" value="729.50" lower_limit="440.00" upper_limit="1012.00"/>
                    <measurement group_id="O3" value="406.50" lower_limit="282.00" upper_limit="685.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="960.50" lower_limit="604.50" upper_limit="1568.00"/>
                    <measurement group_id="O2" value="1105.00" lower_limit="662.00" upper_limit="1958.00"/>
                    <measurement group_id="O3" value="1057.50" lower_limit="855.00" upper_limit="1707.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.00" lower_limit="405.00" upper_limit="708.50"/>
                    <measurement group_id="O2" value="944.50" lower_limit="652.00" upper_limit="1219.00"/>
                    <measurement group_id="O3" value="294.00" lower_limit="173.00" upper_limit="509.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1187.00" lower_limit="729.00" upper_limit="1882.00"/>
                    <measurement group_id="O2" value="1905.50" lower_limit="1019.00" upper_limit="2972.00"/>
                    <measurement group_id="O3" value="1658.50" lower_limit="1093.00" upper_limit="2342.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490.50" lower_limit="364.50" upper_limit="772.50"/>
                    <measurement group_id="O2" value="952.50" lower_limit="665.00" upper_limit="1406.00"/>
                    <measurement group_id="O3" value="357.00" lower_limit="232.50" upper_limit="692.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1360.00" lower_limit="709.00" upper_limit="1925.50"/>
                    <measurement group_id="O2" value="1888.00" lower_limit="894.00" upper_limit="3102.00"/>
                    <measurement group_id="O3" value="1616.50" lower_limit="1307.00" upper_limit="2160.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.00" lower_limit="10.00" upper_limit="205.00"/>
                    <measurement group_id="O2" value="60.50" lower_limit="3.00" upper_limit="256.00"/>
                    <measurement group_id="O3" value="47.50" lower_limit="1.00" upper_limit="170.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.50" lower_limit="30.00" upper_limit="251.00"/>
                    <measurement group_id="O2" value="75.00" lower_limit="1.00" upper_limit="258.00"/>
                    <measurement group_id="O3" value="52.00" lower_limit="25.00" upper_limit="143.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.00" lower_limit="43.50" upper_limit="425.00"/>
                    <measurement group_id="O2" value="99.50" lower_limit="37.00" upper_limit="244.00"/>
                    <measurement group_id="O3" value="90.50" lower_limit="2.00" upper_limit="343.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.50" lower_limit="93.50" upper_limit="463.00"/>
                    <measurement group_id="O2" value="153.00" lower_limit="42.00" upper_limit="316.00"/>
                    <measurement group_id="O3" value="147.50" lower_limit="58.00" upper_limit="357.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="11.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="13.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="25.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="32.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="27.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.50" lower_limit="1.00" upper_limit="116.50"/>
                    <measurement group_id="O2" value="40.00" lower_limit="1.00" upper_limit="190.00"/>
                    <measurement group_id="O3" value="30.50" lower_limit="1.00" upper_limit="113.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" lower_limit="1.00" upper_limit="142.50"/>
                    <measurement group_id="O2" value="39.00" lower_limit="1.00" upper_limit="167.00"/>
                    <measurement group_id="O3" value="39.00" lower_limit="1.00" upper_limit="90.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.50" lower_limit="24.50" upper_limit="150.00"/>
                    <measurement group_id="O2" value="48.50" lower_limit="22.00" upper_limit="178.00"/>
                    <measurement group_id="O3" value="51.00" lower_limit="1.00" upper_limit="183.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.00" lower_limit="39.00" upper_limit="203.50"/>
                    <measurement group_id="O2" value="90.50" lower_limit="29.00" upper_limit="162.00"/>
                    <measurement group_id="O3" value="86.50" lower_limit="31.00" upper_limit="219.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.00" lower_limit="1.00" upper_limit="218.50"/>
                    <measurement group_id="O2" value="40.50" lower_limit="1.00" upper_limit="207.00"/>
                    <measurement group_id="O3" value="37.50" lower_limit="1.00" upper_limit="155.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.50" lower_limit="31.00" upper_limit="261.50"/>
                    <measurement group_id="O2" value="56.50" lower_limit="1.00" upper_limit="255.00"/>
                    <measurement group_id="O3" value="41.00" lower_limit="4.00" upper_limit="136.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.50" lower_limit="27.00" upper_limit="425.00"/>
                    <measurement group_id="O2" value="76.00" lower_limit="35.00" upper_limit="223.00"/>
                    <measurement group_id="O3" value="97.50" lower_limit="16.50" upper_limit="342.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.00" lower_limit="82.50" upper_limit="444.00"/>
                    <measurement group_id="O2" value="127.00" lower_limit="38.00" upper_limit="287.00"/>
                    <measurement group_id="O3" value="149.00" lower_limit="58.00" upper_limit="350.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00" lower_limit="1.00" upper_limit="177.50"/>
                    <measurement group_id="O2" value="47.00" lower_limit="1.00" upper_limit="161.00"/>
                    <measurement group_id="O3" value="28.00" lower_limit="1.00" upper_limit="138.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.50" lower_limit="26.00" upper_limit="239.00"/>
                    <measurement group_id="O2" value="75.50" lower_limit="1.00" upper_limit="162.00"/>
                    <measurement group_id="O3" value="36.50" lower_limit="1.00" upper_limit="89.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.50" lower_limit="18.50" upper_limit="425.00"/>
                    <measurement group_id="O2" value="83.00" lower_limit="25.00" upper_limit="178.00"/>
                    <measurement group_id="O3" value="71.00" lower_limit="1.00" upper_limit="208.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.00" lower_limit="41.50" upper_limit="429.00"/>
                    <measurement group_id="O2" value="98.00" lower_limit="32.00" upper_limit="246.00"/>
                    <measurement group_id="O3" value="136.00" lower_limit="1.00" upper_limit="350.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</title>
        <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed were H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
        <time_frame>At Months 6, 12, 18 and 24</time_frame>
        <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Non-AD F1 Primed Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines</title>
          <description>Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed were H5N1 A/Indonesia and H5N1 A/Vietnam.</description>
          <population>The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.</population>
          <units>T-cell/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1575.00" lower_limit="1157.00" upper_limit="2247.00"/>
                    <measurement group_id="O2" value="1244.00" lower_limit="919.00" upper_limit="1816.00"/>
                    <measurement group_id="O3" value="1817.00" lower_limit="1296.00" upper_limit="2235.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1710.00" lower_limit="1063.00" upper_limit="2393.00"/>
                    <measurement group_id="O2" value="1138.00" lower_limit="929.00" upper_limit="1677.00"/>
                    <measurement group_id="O3" value="1775.00" lower_limit="1208.00" upper_limit="2156.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1605.00" lower_limit="1157.00" upper_limit="2199.00"/>
                    <measurement group_id="O2" value="1190.00" lower_limit="903.00" upper_limit="1734.00"/>
                    <measurement group_id="O3" value="1720.00" lower_limit="1202.00" upper_limit="2188.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1724.00" lower_limit="1049.00" upper_limit="2281.00"/>
                    <measurement group_id="O2" value="1124.00" lower_limit="890.00" upper_limit="1636.00"/>
                    <measurement group_id="O3" value="1748.00" lower_limit="1140.00" upper_limit="2169.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1454.00" lower_limit="1031.00" upper_limit="2111.00"/>
                    <measurement group_id="O2" value="1136.00" lower_limit="780.00" upper_limit="1683.00"/>
                    <measurement group_id="O3" value="1736.00" lower_limit="1140.00" upper_limit="2122.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1481.00" lower_limit="979.00" upper_limit="2183.00"/>
                    <measurement group_id="O2" value="1070.00" lower_limit="782.00" upper_limit="1555.00"/>
                    <measurement group_id="O3" value="1580.00" lower_limit="1070.00" upper_limit="2023.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794.00" lower_limit="516.00" upper_limit="1228.00"/>
                    <measurement group_id="O2" value="636.00" lower_limit="411.00" upper_limit="1015.00"/>
                    <measurement group_id="O3" value="929.00" lower_limit="571.00" upper_limit="1235.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876.00" lower_limit="547.00" upper_limit="1376.00"/>
                    <measurement group_id="O2" value="679.00" lower_limit="413.00" upper_limit="914.00"/>
                    <measurement group_id="O3" value="885.00" lower_limit="599.00" upper_limit="1284.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152.00" lower_limit="848.00" upper_limit="1836.00"/>
                    <measurement group_id="O2" value="920.00" lower_limit="698.00" upper_limit="1322.00"/>
                    <measurement group_id="O3" value="1467.00" lower_limit="1004.00" upper_limit="1890.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279.00" lower_limit="860.00" upper_limit="1984.00"/>
                    <measurement group_id="O2" value="941.00" lower_limit="716.00" upper_limit="1169.00"/>
                    <measurement group_id="O3" value="1292.00" lower_limit="936.00" upper_limit="1771.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1333.00" lower_limit="903.00" upper_limit="1981.00"/>
                    <measurement group_id="O2" value="786.50" lower_limit="560.50" upper_limit="1074.50"/>
                    <measurement group_id="O3" value="1332.50" lower_limit="846.00" upper_limit="1566.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1171.00" lower_limit="813.00" upper_limit="1851.00"/>
                    <measurement group_id="O2" value="796.50" lower_limit="591.50" upper_limit="1148.50"/>
                    <measurement group_id="O3" value="1225.00" lower_limit="786.00" upper_limit="1565.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1119.00" lower_limit="580.00" upper_limit="1604.00"/>
                    <measurement group_id="O2" value="647.00" lower_limit="406.50" upper_limit="938.50"/>
                    <measurement group_id="O3" value="1159.00" lower_limit="746.00" upper_limit="1472.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090.00" lower_limit="728.00" upper_limit="1632.00"/>
                    <measurement group_id="O2" value="641.00" lower_limit="395.50" upper_limit="947.00"/>
                    <measurement group_id="O3" value="1134.00" lower_limit="679.50" upper_limit="1355.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1290.00" lower_limit="860.00" upper_limit="1826.00"/>
                    <measurement group_id="O2" value="721.00" lower_limit="490.50" upper_limit="1038.00"/>
                    <measurement group_id="O3" value="1219.50" lower_limit="805.00" upper_limit="1525.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1183.00" lower_limit="746.00" upper_limit="1842.00"/>
                    <measurement group_id="O2" value="733.00" lower_limit="540.00" upper_limit="1055.00"/>
                    <measurement group_id="O3" value="1100.00" lower_limit="745.00" upper_limit="1466.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="746.00" lower_limit="485.00" upper_limit="958.00"/>
                    <measurement group_id="O2" value="432.50" lower_limit="346.00" upper_limit="657.50"/>
                    <measurement group_id="O3" value="618.00" lower_limit="382.50" upper_limit="839.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670.00" lower_limit="512.00" upper_limit="1033.00"/>
                    <measurement group_id="O2" value="497.50" lower_limit="299.00" upper_limit="679.50"/>
                    <measurement group_id="O3" value="643.00" lower_limit="372.50" upper_limit="979.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1065.00" lower_limit="692.00" upper_limit="1623.00"/>
                    <measurement group_id="O2" value="551.50" lower_limit="432.00" upper_limit="814.50"/>
                    <measurement group_id="O3" value="997.50" lower_limit="665.50" upper_limit="1272.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945.00" lower_limit="728.00" upper_limit="1534.00"/>
                    <measurement group_id="O2" value="616.50" lower_limit="474.50" upper_limit="796.00"/>
                    <measurement group_id="O3" value="939.50" lower_limit="620.00" upper_limit="1226.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1421.00" lower_limit="959.00" upper_limit="2106.00"/>
                    <measurement group_id="O2" value="1052.00" lower_limit="748.00" upper_limit="1705.00"/>
                    <measurement group_id="O3" value="1392.00" lower_limit="1119.00" upper_limit="2003.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1536.00" lower_limit="893.00" upper_limit="2061.00"/>
                    <measurement group_id="O2" value="1022.00" lower_limit="699.00" upper_limit="1665.00"/>
                    <measurement group_id="O3" value="1367.00" lower_limit="995.00" upper_limit="1650.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1369.00" lower_limit="869.00" upper_limit="2080.00"/>
                    <measurement group_id="O2" value="1013.00" lower_limit="733.00" upper_limit="1679.00"/>
                    <measurement group_id="O3" value="1330.00" lower_limit="1083.00" upper_limit="1937.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1523.00" lower_limit="821.00" upper_limit="2088.00"/>
                    <measurement group_id="O2" value="1036.00" lower_limit="634.00" upper_limit="1653.00"/>
                    <measurement group_id="O3" value="1288.00" lower_limit="997.00" upper_limit="1642.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1316.00" lower_limit="829.00" upper_limit="1868.00"/>
                    <measurement group_id="O2" value="946.00" lower_limit="613.00" upper_limit="1434.00"/>
                    <measurement group_id="O3" value="1170.00" lower_limit="929.00" upper_limit="1511.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1346.00" lower_limit="817.00" upper_limit="1942.00"/>
                    <measurement group_id="O2" value="933.00" lower_limit="578.00" upper_limit="1354.00"/>
                    <measurement group_id="O3" value="1062.00" lower_limit="925.00" upper_limit="1475.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="906.00" lower_limit="553.00" upper_limit="1592.00"/>
                    <measurement group_id="O2" value="729.00" lower_limit="490.00" upper_limit="1158.00"/>
                    <measurement group_id="O3" value="865.00" lower_limit="655.00" upper_limit="1424.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1042.00" lower_limit="560.00" upper_limit="1519.00"/>
                    <measurement group_id="O2" value="743.00" lower_limit="523.00" upper_limit="1292.00"/>
                    <measurement group_id="O3" value="965.00" lower_limit="670.00" upper_limit="1343.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1173.00" lower_limit="764.00" upper_limit="1600.00"/>
                    <measurement group_id="O2" value="811.00" lower_limit="577.00" upper_limit="1142.00"/>
                    <measurement group_id="O3" value="1035.00" lower_limit="824.00" upper_limit="1490.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1074.00" lower_limit="693.00" upper_limit="1623.00"/>
                    <measurement group_id="O2" value="793.00" lower_limit="563.00" upper_limit="1195.00"/>
                    <measurement group_id="O3" value="1079.00" lower_limit="748.00" upper_limit="1431.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1307.00" lower_limit="946.00" upper_limit="1588.00"/>
                    <measurement group_id="O2" value="914.00" lower_limit="759.00" upper_limit="1381.00"/>
                    <measurement group_id="O3" value="1306.00" lower_limit="795.00" upper_limit="1632.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1229.00" lower_limit="872.00" upper_limit="1746.00"/>
                    <measurement group_id="O2" value="850.00" lower_limit="565.00" upper_limit="1327.00"/>
                    <measurement group_id="O3" value="1322.00" lower_limit="877.00" upper_limit="1606.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1220.00" lower_limit="893.00" upper_limit="1585.00"/>
                    <measurement group_id="O2" value="917.00" lower_limit="745.00" upper_limit="1237.00"/>
                    <measurement group_id="O3" value="1280.00" lower_limit="739.00" upper_limit="1580.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 CD40L - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1195.00" lower_limit="885.00" upper_limit="1733.00"/>
                    <measurement group_id="O2" value="826.00" lower_limit="565.00" upper_limit="1314.00"/>
                    <measurement group_id="O3" value="1356.00" lower_limit="851.00" upper_limit="1576.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146.00" lower_limit="796.00" upper_limit="1402.00"/>
                    <measurement group_id="O2" value="867.00" lower_limit="692.00" upper_limit="1139.00"/>
                    <measurement group_id="O3" value="1105.00" lower_limit="646.00" upper_limit="1460.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 IL-2 - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1101.00" lower_limit="787.00" upper_limit="1533.00"/>
                    <measurement group_id="O2" value="839.00" lower_limit="493.00" upper_limit="1211.00"/>
                    <measurement group_id="O3" value="1253.00" lower_limit="686.00" upper_limit="1369.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848.00" lower_limit="597.00" upper_limit="1124.00"/>
                    <measurement group_id="O2" value="654.00" lower_limit="492.00" upper_limit="975.00"/>
                    <measurement group_id="O3" value="860.00" lower_limit="458.00" upper_limit="1087.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 INF-γ - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838.00" lower_limit="517.00" upper_limit="1031.00"/>
                    <measurement group_id="O2" value="704.00" lower_limit="464.00" upper_limit="991.00"/>
                    <measurement group_id="O3" value="888.00" lower_limit="512.00" upper_limit="1130.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062.00" lower_limit="730.00" upper_limit="1306.00"/>
                    <measurement group_id="O2" value="773.00" lower_limit="654.00" upper_limit="965.00"/>
                    <measurement group_id="O3" value="1186.00" lower_limit="627.00" upper_limit="1437.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 TNF-α - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999.00" lower_limit="770.00" upper_limit="1253.00"/>
                    <measurement group_id="O2" value="680.00" lower_limit="441.00" upper_limit="1085.00"/>
                    <measurement group_id="O3" value="1023.00" lower_limit="593.00" upper_limit="1329.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.00" lower_limit="1.00" upper_limit="184.00"/>
                    <measurement group_id="O2" value="79.00" lower_limit="16.00" upper_limit="264.00"/>
                    <measurement group_id="O3" value="89.00" lower_limit="1.00" upper_limit="199.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.00" lower_limit="53.00" upper_limit="288.00"/>
                    <measurement group_id="O2" value="139.00" lower_limit="61.00" upper_limit="286.00"/>
                    <measurement group_id="O3" value="107.00" lower_limit="1.00" upper_limit="241.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="23.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.00" lower_limit="1.00" upper_limit="107.00"/>
                    <measurement group_id="O2" value="54.00" lower_limit="1.00" upper_limit="240.00"/>
                    <measurement group_id="O3" value="53.00" lower_limit="1.00" upper_limit="115.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.00" lower_limit="18.00" upper_limit="227.00"/>
                    <measurement group_id="O2" value="77.00" lower_limit="27.00" upper_limit="182.00"/>
                    <measurement group_id="O3" value="63.00" lower_limit="1.00" upper_limit="158.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.00" lower_limit="1.00" upper_limit="158.00"/>
                    <measurement group_id="O2" value="49.00" lower_limit="1.00" upper_limit="202.00"/>
                    <measurement group_id="O3" value="44.00" lower_limit="1.00" upper_limit="165.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" lower_limit="1.00" upper_limit="239.00"/>
                    <measurement group_id="O2" value="117.00" lower_limit="21.00" upper_limit="246.00"/>
                    <measurement group_id="O3" value="61.00" lower_limit="1.00" upper_limit="221.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.00" lower_limit="1.00" upper_limit="99.00"/>
                    <measurement group_id="O2" value="71.00" lower_limit="1.00" upper_limit="216.00"/>
                    <measurement group_id="O3" value="76.00" lower_limit="1.00" upper_limit="146.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.00" lower_limit="18.00" upper_limit="218.00"/>
                    <measurement group_id="O2" value="123.00" lower_limit="59.00" upper_limit="246.00"/>
                    <measurement group_id="O3" value="80.00" lower_limit="1.00" upper_limit="215.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.00" lower_limit="26.00" upper_limit="166.00"/>
                    <measurement group_id="O2" value="73.00" lower_limit="3.00" upper_limit="172.00"/>
                    <measurement group_id="O3" value="30.50" lower_limit="1.00" upper_limit="94.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.00" lower_limit="21.00" upper_limit="210.00"/>
                    <measurement group_id="O2" value="95.00" lower_limit="17.00" upper_limit="293.00"/>
                    <measurement group_id="O3" value="31.50" lower_limit="1.00" upper_limit="104.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.00" lower_limit="2.00" upper_limit="166.00"/>
                    <measurement group_id="O2" value="54.50" lower_limit="1.00" upper_limit="117.50"/>
                    <measurement group_id="O3" value="5.50" lower_limit="1.00" upper_limit="82.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.00" lower_limit="1.00" upper_limit="142.00"/>
                    <measurement group_id="O2" value="49.50" lower_limit="2.00" upper_limit="186.00"/>
                    <measurement group_id="O3" value="13.00" lower_limit="1.00" upper_limit="78.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.00" lower_limit="1.00" upper_limit="168.00"/>
                    <measurement group_id="O2" value="60.50" lower_limit="1.00" upper_limit="159.50"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="80.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.00" lower_limit="31.00" upper_limit="205.00"/>
                    <measurement group_id="O2" value="54.00" lower_limit="13.00" upper_limit="263.50"/>
                    <measurement group_id="O3" value="32.00" lower_limit="1.00" upper_limit="131.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.00" lower_limit="11.00" upper_limit="109.00"/>
                    <measurement group_id="O2" value="62.00" lower_limit="1.00" upper_limit="117.50"/>
                    <measurement group_id="O3" value="23.50" lower_limit="1.00" upper_limit="66.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.00" lower_limit="1.00" upper_limit="158.00"/>
                    <measurement group_id="O2" value="75.50" lower_limit="7.00" upper_limit="224.00"/>
                    <measurement group_id="O3" value="31.50" lower_limit="1.00" upper_limit="92.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="1.00" upper_limit="208.00"/>
                    <measurement group_id="O2" value="82.00" lower_limit="1.00" upper_limit="160.00"/>
                    <measurement group_id="O3" value="40.00" lower_limit="1.00" upper_limit="127.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" lower_limit="1.00" upper_limit="138.00"/>
                    <measurement group_id="O2" value="66.00" lower_limit="28.00" upper_limit="214.00"/>
                    <measurement group_id="O3" value="119.00" lower_limit="28.00" upper_limit="270.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="29.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="64.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="75.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="68.00"/>
                    <measurement group_id="O2" value="43.00" lower_limit="1.00" upper_limit="99.00"/>
                    <measurement group_id="O3" value="30.00" lower_limit="1.00" upper_limit="90.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="98.00"/>
                    <measurement group_id="O2" value="40.00" lower_limit="1.00" upper_limit="170.00"/>
                    <measurement group_id="O3" value="47.00" lower_limit="1.00" upper_limit="79.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.00" lower_limit="1.00" upper_limit="177.00"/>
                    <measurement group_id="O2" value="82.00" lower_limit="1.00" upper_limit="162.00"/>
                    <measurement group_id="O3" value="31.00" lower_limit="1.00" upper_limit="127.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" lower_limit="1.00" upper_limit="138.00"/>
                    <measurement group_id="O2" value="62.00" lower_limit="9.00" upper_limit="214.00"/>
                    <measurement group_id="O3" value="119.00" lower_limit="24.00" upper_limit="270.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="157.00"/>
                    <measurement group_id="O2" value="81.00" lower_limit="1.00" upper_limit="205.00"/>
                    <measurement group_id="O3" value="42.00" lower_limit="1.00" upper_limit="109.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.00" lower_limit="1.00" upper_limit="132.00"/>
                    <measurement group_id="O2" value="65.00" lower_limit="22.00" upper_limit="240.00"/>
                    <measurement group_id="O3" value="107.00" lower_limit="30.00" upper_limit="158.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.00" lower_limit="1.00" upper_limit="167.00"/>
                    <measurement group_id="O2" value="73.00" lower_limit="1.00" upper_limit="247.00"/>
                    <measurement group_id="O3" value="65.00" lower_limit="1.00" upper_limit="148.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.00" lower_limit="1.00" upper_limit="243.00"/>
                    <measurement group_id="O2" value="73.00" lower_limit="1.00" upper_limit="193.00"/>
                    <measurement group_id="O3" value="102.00" lower_limit="1.00" upper_limit="269.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.00" lower_limit="1.00" upper_limit="65.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="36.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="44.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 CD40L - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="47.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="44.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="93.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" lower_limit="1.00" upper_limit="62.00"/>
                    <measurement group_id="O2" value="25.00" lower_limit="1.00" upper_limit="115.00"/>
                    <measurement group_id="O3" value="32.00" lower_limit="1.00" upper_limit="68.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 IL-2 - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="77.00"/>
                    <measurement group_id="O2" value="26.00" lower_limit="1.00" upper_limit="99.00"/>
                    <measurement group_id="O3" value="31.00" lower_limit="1.00" upper_limit="130.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.00" lower_limit="1.00" upper_limit="167.00"/>
                    <measurement group_id="O2" value="93.00" lower_limit="1.00" upper_limit="231.00"/>
                    <measurement group_id="O3" value="65.00" lower_limit="1.00" upper_limit="143.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 INF-γ - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" lower_limit="1.00" upper_limit="243.00"/>
                    <measurement group_id="O2" value="73.00" lower_limit="1.00" upper_limit="193.00"/>
                    <measurement group_id="O3" value="102.00" lower_limit="22.00" upper_limit="231.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Indonesia, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.00" lower_limit="1.00" upper_limit="128.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="1.00" upper_limit="153.00"/>
                    <measurement group_id="O3" value="55.00" lower_limit="1.00" upper_limit="89.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 TNF-α - H5N1 A/Vietnam, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.00" lower_limit="1.00" upper_limit="174.00"/>
                    <measurement group_id="O2" value="45.00" lower_limit="1.00" upper_limit="148.00"/>
                    <measurement group_id="O3" value="64.00" lower_limit="1.00" upper_limit="182.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events (AEs): during the 21-day (Days 0-20) or 30-day (Days 0-29) post-vaccination 1 period and the 30-day (Days 0-29) post-vaccination 2 period; Serious adverse events (SAEs): during the whole study period (from Day 0 up to Month 24).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1562902A Non-AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK1562902A Non-AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK1562902A Non-AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>GSK1562902A Non-AD F4 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Control Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E6">
          <title>GSK1562902A AD F1 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E7">
          <title>GSK1562902A AD F2 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E8">
          <title>GSK1562902A AD F3 Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E9">
          <title>GSK1562902A AD Approved F Primed Group</title>
          <description>Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>High grade b-cell lymphoma burkitt-like lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="35"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E9" subjects_affected="33" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E5" events="21" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E4" events="28" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E5" events="51" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E8" events="19" subjects_affected="18" subjects_at_risk="41"/>
                <counts group_id="E9" events="14" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="61" subjects_affected="34" subjects_at_risk="36"/>
                <counts group_id="E2" events="65" subjects_affected="36" subjects_at_risk="40"/>
                <counts group_id="E3" events="56" subjects_affected="32" subjects_at_risk="37"/>
                <counts group_id="E4" events="62" subjects_affected="35" subjects_at_risk="36"/>
                <counts group_id="E5" events="87" subjects_affected="47" subjects_at_risk="50"/>
                <counts group_id="E6" events="38" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E7" events="35" subjects_affected="34" subjects_at_risk="35"/>
                <counts group_id="E8" events="40" subjects_affected="39" subjects_at_risk="41"/>
                <counts group_id="E9" events="32" subjects_affected="31" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E5" events="20" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="36"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E3" events="23" subjects_affected="15" subjects_at_risk="37"/>
                <counts group_id="E4" events="19" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E5" events="42" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E8" events="12" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E9" events="10" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="33" subjects_affected="22" subjects_at_risk="36"/>
                <counts group_id="E2" events="30" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E3" events="32" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E4" events="30" subjects_affected="18" subjects_at_risk="36"/>
                <counts group_id="E5" events="49" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E6" events="23" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E7" events="13" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E8" events="15" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E9" events="14" subjects_affected="11" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E5" events="20" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

